Drug Insights

Is Pralsetinib approved by the FDA?

5 July 2024
3 min read

Yes, pralsetinib (Gavreto) is an FDA-approved medication for treating RET fusion-positive non-small cell lung cancer and certain thyroid cancers. Approved on September 4, 2020, it represents a significant advancement in targeted cancer therapy.

What is Pralsetinib?

Pralsetinib is a multikinase inhibitor used to treat specific types of cancer, primarily non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. It is specifically used for cancers that exhibit a genetic marker known as "RET" gene fusion. Your doctor will test for this genetic marker to determine if pralsetinib is appropriate for your treatment.

How Pralsetinib Works

Pralsetinib targets and inhibits the activity of certain proteins involved in the growth and spread of cancer cells, specifically those with RET gene fusions. By inhibiting these proteins, pralsetinib can help slow down or stop the progression of the cancer.

Administration and Dosage

  • Dosage Form: Oral capsule (100 mg)
  • Recommended Dose: 400 mg orally once daily on an empty stomach (at least 1 hour before or 2 hours after a meal)
  • Duration: Continue until disease progression or unacceptable toxicity occurs

Potential Side Effects

Common Side Effects:

  • High blood pressure
  • Low blood cell counts or other abnormal laboratory tests
  • Muscle or joint pain
  • Fatigue
  • Constipation

Serious Side Effects:

  • Fever, chills
  • New or worsening cough, shortness of breath, chest pain
  • Severe headache, dizziness, confusion, trouble speaking
  • Wound that will not heal
  • Unusual bleeding or bruising
  • Signs of bleeding inside the body (e.g., bloody or tarry stools, coughing up blood)
  • Liver problems (e.g., nausea, vomiting, jaundice)

Patients should report any severe or unusual symptoms to their doctor immediately.

Warnings and Precautions

  • Pregnancy and Birth Control: Pralsetinib can harm an unborn baby. Women should use effective non-hormonal birth control during treatment and for at least 2 weeks after the last dose. Men should use effective birth control if their partner can become pregnant, continuing for at least 1 week after the last dose.
  • Breastfeeding: Do not breastfeed during treatment and for at least 1 week after the last dose.
  • Pre-existing Conditions: Inform your doctor if you have a history of lung or breathing problems, bleeding issues, or high blood pressure.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

What are the prospects for the AOC therapy that boosted Avidity by 33%?
Hot Spotlight
10 min read
What are the prospects for the AOC therapy that boosted Avidity by 33%?
5 July 2024
Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.
Read →
Is Detectnet approved by the FDA?
Drug Insights
3 min read
Is Detectnet approved by the FDA?
5 July 2024
Approved on September 3, 2020, Detectnet (copper Cu 64 dotatate) provides a critical tool for the diagnosis and management of NETs.
Read →
FDA Approves KaliVir Immunotherapeutics' VET3-TGI for Solid Tumor Immunotherapy
Latest Hotspot
3 min read
FDA Approves KaliVir Immunotherapeutics' VET3-TGI for Solid Tumor Immunotherapy
5 July 2024
KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.
Read →
Is Somapacitan approved by the FDA?
Drug Insights
3 min read
Is Somapacitan approved by the FDA?
5 July 2024
Approved on August 28, 2020, somapacitan (Sogroya) offers a convenient once-weekly injection, improving adherence and quality of life for patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.